These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 29247857)

  • 21. Development of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitor for Brain and Cancer PET Imaging.
    Huang CH; Khan P; Xu S; Cohen J; Georgakis GV; Turkman N
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
    Salphati L; Heffron TP; Alicke B; Nishimura M; Barck K; Carano RA; Cheong J; Edgar KA; Greve J; Kharbanda S; Koeppen H; Lau S; Lee LB; Pang J; Plise EG; Pokorny JL; Reslan HB; Sarkaria JN; Wallin JJ; Zhang X; Gould SE; Olivero AG; Phillips HS
    Clin Cancer Res; 2012 Nov; 18(22):6239-48. PubMed ID: 22992516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclin D-CDK4/6 functions in cancer.
    Gao X; Leone GW; Wang H
    Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
    Xiong Y; Li T; Assani G; Ling H; Zhou Q; Zeng Y; Zhou F; Zhou Y
    Biomed Pharmacother; 2019 Apr; 112():108602. PubMed ID: 30784916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
    Nepali K; Hsu TI; Hsieh CM; Lo WL; Lai MJ; Hsu KC; Lin TE; Chuang JY; Liou JP
    Eur J Med Chem; 2021 May; 217():113338. PubMed ID: 33744690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme.
    Qiu S; Huang D; Yin D; Li F; Li X; Kung HF; Peng Y
    Biochim Biophys Acta; 2013 Oct; 1832(10):1697-707. PubMed ID: 23707559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
    Cao Y; Li X; Kong S; Shang S; Qi Y
    J Cell Mol Med; 2020 May; 24(9):5135-5145. PubMed ID: 32277580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors.
    Zhao H; Hu X; Cao K; Zhang Y; Zhao K; Tang C; Feng B
    Eur J Med Chem; 2018 Sep; 157():935-945. PubMed ID: 30165341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
    O'Sullivan CC
    Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of pteridin-7(8H)-one analogues as highly potent cyclin-dependent kinase 4/6 inhibitors: Synthesis, structure-activity relationship, and biological activity.
    Li Q; Chen L; Ma YF; Jian XE; Ji JH; You WW; Zhao PL
    Bioorg Chem; 2021 Nov; 116():105324. PubMed ID: 34509794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.
    Tien AC; Li J; Bao X; Derogatis A; Kim S; Mehta S; Sanai N
    Clin Cancer Res; 2019 Oct; 25(19):5777-5786. PubMed ID: 31285369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct inhibition of retinoblastoma phosphorylation by nimbolide causes cell-cycle arrest and suppresses glioblastoma growth.
    Karkare S; Chhipa RR; Anderson J; Liu X; Henry H; Gasilina A; Nassar N; Ghosh J; Clark JP; Kumar A; Pauletti GM; Ghosh PK; Dasgupta B
    Clin Cancer Res; 2014 Jan; 20(1):199-212. PubMed ID: 24170547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.
    Wiedemeyer WR; Dunn IF; Quayle SN; Zhang J; Chheda MG; Dunn GP; Zhuang L; Rosenbluh J; Chen S; Xiao Y; Shapiro GI; Hahn WC; Chin L
    Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11501-6. PubMed ID: 20534551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CDK4/6 inhibitors in breast cancer.
    Dukelow T; Kishan D; Khasraw M; Murphy CG
    Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
    Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
    J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells.
    Morris-Hanon O; Marazita MC; Romorini L; Isaja L; Fernandez-Espinosa DD; Sevlever GE; Scassa ME; Videla-Richardson GA
    Mol Neurobiol; 2019 Nov; 56(11):7810-7821. PubMed ID: 31124078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.
    Klein ME; Kovatcheva M; Davis LE; Tap WD; Koff A
    Cancer Cell; 2018 Jul; 34(1):9-20. PubMed ID: 29731395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The transcriptome of CDK4/6 inhibition.
    Knudsen ES; Witkiewicz AK
    Aging (Albany NY); 2017 Aug; 9(8):1859-1860. PubMed ID: 28860413
    [No Abstract]   [Full Text] [Related]  

  • 40. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
    Logan JE; Mostofizadeh N; Desai AJ; VON Euw E; Conklin D; Konkankit V; Hamidi H; Eckardt M; Anderson L; Chen HW; Ginther C; Taschereau E; Bui PH; Christensen JG; Belldegrun AS; Slamon DJ; Kabbinavar FF
    Anticancer Res; 2013 Aug; 33(8):2997-3004. PubMed ID: 23898052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.